Effect of resveratrol on non‑alcoholic fatty liver disease

Theodotou,Marios; Fokianos,Konstantinos; Moniatis,Demetris; Kadlenic,Rudolf; Chrysikou,Asimina; Aristotelous,Andrea; Mouzouridou,Alexia; Diakides,John; Stavrou,Eliza

doi:10.3892/etm.2019.7607

Effect of resveratrol on non‑alcoholic fatty liver disease

Authors:
- Marios Theodotou
- Konstantinos Fokianos
- Demetris Moniatis
- Rudolf Kadlenic
- Asimina Chrysikou
- Andrea Aristotelous
- Alexia Mouzouridou
- John Diakides
- Eliza Stavrou
View Affiliations

Affiliations: Private Practice, Limassol 3020, Cyprus, Department of Mathematics and Statistics, University of Cyprus, Nicosia 20537, Cyprus, Riegler Ltd., Institute of Medical Clinical Trials, Limassol 3020, Cyprus, Agios Efrem, Advanced Medical Diagnostic Center, Limassol 3020, Cyprus
Published online on: May 23, 2019 https://doi.org/10.3892/etm.2019.7607
Pages: 559-565
Copyright: © Theodotou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of a micronized formulation of trans‑resveratrol in humans with non‑alcoholic fatty liver disease (NAFLD). Trans‑Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement. Resveratrol (3,5,4'‑trihydroxy‑trans‑stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem involving the liver for which effective treatments are required. The present study was based on two patient groups. The study, which commenced on April 2013 and finished on April 2015, included 44 patients, aged 29‑70 years, with an average weight of 84.6 kg (n=22 per group; 28 men and 16 women) who were randomly assigned to groups and given 50 mg Evelor capsule (n=22) and 200 mg Evelor H tablet (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurements, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study results showed the effects of Trans‑resveratrol micronized formulation in reducing the liver fat, as well as decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma‑glutamyl transpeptidase (g‑GT) and insulin resistance. At the end of the study, the statistical analysis showed a statistically significant reduction on the liver fat. These data demonstrate that use of Trans‑resveratrol micronized formulation improves features of NAFLD, and prevents liver damage. Thus, Trans‑resveratrol micronized formulation can be a new treatment method for NAFLD.

View Figures

View References

1	Vernon G, Baranova A and Younossi ZM: Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55:2005–2023. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, et al: Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 12:2092–2103.e1-e6. 2014. View Article : Google Scholar : PubMed/NCBI
4	Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 141:1249–1253. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bonora E and Targher G: Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 9:372–381. 2012. View Article : Google Scholar : PubMed/NCBI
6	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
7	Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A and Fargion S: Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 121:72–78. 2008. View Article : Google Scholar : PubMed/NCBI
8	Frémont L: Biological effects of resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar : PubMed/NCBI
9	Kopec KL and Burns D: Nonalcoholic fatty liver disease: A review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 26:565–576. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 127:1109–1122. 2006. View Article : Google Scholar : PubMed/NCBI
11	Gómez-Zorita S, Fernández-Quintela A, Macarulla M, Aguirre L, Hijona E, Bujanda L, Milagro F, Martínez JA and Portillo MP: Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 107:202–210. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY and Mao YM; Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease, : Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 9:108–112. 2008. View Article : Google Scholar : PubMed/NCBI
13	Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS and Gao X: Standaridized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: An improvement method. Obesity (Silver Spring). 20:444–452. 2012. View Article : Google Scholar : PubMed/NCBI
14	von Volkmann HL, Havre RF, Løberg EM, Haaland T, Immervoll H, Haukeland JW, Hausken T and Gilja OH: Quantitative measurement of ultrasound attenuation and hepato-renal index in non-alcoholic fatty liver disease. Med Ultrason. 15:16–22. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ramadori G, Moriconi F, Malik I and Dudas J: Physiology and pathophysiology of liver inflammation damage and repair. J Physiol Pharmacol. 59 (Suppl 1):S107–S117. 2008.
16	Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D and Lemasters JJ: Mechanisms of hepatotoxicity. Toxicol Sci. 65:166–176. 2002. View Article : Google Scholar : PubMed/NCBI
17	Tietz Textbook of clinical chemistry, . Burtis CA, Ashwood ER and Saunders WB; Company, : Philadelphia: 1994
18	Clark JM, Brancati FL and Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 98:960–967. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
20	Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A and Angulo P: The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 129:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
21	Paschos P and Paletas K: Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 13:9–19. 2009.PubMed/NCBI
22	Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L and Velagić V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 13:4539–4550. 2007. View Article : Google Scholar : PubMed/NCBI
23	Alberti KG, Zimmet P and Shaw J; IDF Epidemiology Task Force Consensus Group, : The metabolic syndrome-a new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI
24	Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI
25	Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, et al: Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444:337–342. 2006. View Article : Google Scholar : PubMed/NCBI
26	Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, et al: SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15:675–690. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yang YM, Han CY, Kim YJ and Kim SG: AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability. World J Gastroenterol. 16:3731–3742. 2010. View Article : Google Scholar : PubMed/NCBI
28	Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al: AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13:376–388. 2011. View Article : Google Scholar : PubMed/NCBI
29	Alberdi G, Rodríguez VM, Macarulla MT, Miranda J, Churruca I and Portillo MP: Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition. 29:562–567. 2013. View Article : Google Scholar : PubMed/NCBI
30	Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, Doganay L and Enc FY: SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 17:HY5–HY9. 2011. View Article : Google Scholar : PubMed/NCBI
31	Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X and Li X: Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
32	Li L, Hai J, Li Z, Zhang Y, Peng H, Li K and Weng X: Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 263:166–173. 2014. View Article : Google Scholar
33	Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H and Rodrigues CM: miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 58:119–125. 2013. View Article : Google Scholar : PubMed/NCBI